Clinical trials: Epirubicin
Breast Cancer
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
Some chemotherapies, including docetaxel, are better tolerated and just as effective when giving the dose weekly rather than on an every three week basis.
- Trial name
- BREAST-10 (NCT00540800)
- Testing
- docetaxel, epirubicin, capecitabine
- Where
- 3 sites in Italy
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute, Naples
Breast Cancer
Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00253500
- Testing
- pegfilgrastim, epirubicin hydrochloride, conventional surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Case Comprehensive Cancer Center
Hepatocellular Carcinoma
SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma
This study is open to patients with primary HCC who cannot be treated by potentially curative treatment modalities, such as surgical resection, liver transplantation or percutaneous ablation.
- Trial name
- SIRTACE (NCT00867750)
- Testing
- Radioembolisation (SIR-Spheres® microspheres), Transarterial Chemoembolisation
- Where
- 2 sites in Germany, Spain
- Volunteers
- 28 people
- Sponsor
- Sirtex Medical
Esophageal Cancer, Gastric Cancer
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00052910
- Testing
- cisplatin, epirubicin hydrochloride, fluorouracil
- Where
- 535 sites in United States, Canada
- Volunteers
- 546 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatocellular Carcinoma
Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;
This is a multicenter, randomized, parallel controlled study to determine the efficacy and safety of transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma beyond University of California, San…
- Trial name
- NCT04738188
- Testing
- DEB-TACE, cTACE, Drug-eluting Beads
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Breast Cancer
Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00039546
- Testing
- cyclophosphamide, epirubicin hydrochloride, gemcitabine hydrochloride
- Where
- 46 sites in United Kingdom
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)
Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)
A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of GSMs-TACE Combined with Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) with Type III Portal Vein Tumor Thrombus…
- Trial name
- NCT04619342
- Testing
- GSMs-TACE, Surgical Resection
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Chemotherapy-Induced Neutropenia, Myelosuppression
Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
Neutropenia is the most serious hematologic toxicity of cancer chemotherapy, often limiting the doses and density of chemotherapy that can be tolerated. The degree and duration of neutropenia determine the risk of infection.
- Conditions
- Chemotherapy-Induced Neutropenia, Myelosuppression, Breast Cancer
- Trial name
- MyeloConcept (NCT02692742)
- Testing
- Myelo001
- Where
- 23 sites in Germany
- Volunteers
- 137 people
- Sponsor
- Myelo Therapeutics GmbH
Esophageal Cancer, Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
The purpose of this study is to see whether giving azacitidine before each cycle of chemotherapy prior to surgery is safe.
- Trial name
- VEOX (NCT01386346)
- Testing
- Azacitidine, Oxaliplatin, Epirubicin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Weill Medical College of Cornell University
Liver Cancer, Pancreatic Cancer
Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos
The study consists in a co-clinical trial by using zebrafish embryos. Specifically, an observational prospective clinical trial on patients operated of epato-biliar-pancreatic cancers and gastro-intestinal cancers undergoing a…
- Conditions
- Liver Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- xenoZ (NCT03668418)
- Testing
- Fluorouracil, Lederfolin, Oxaliplatin
- Where
- Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Breast Cancer
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
The goal of this clinical research study is to learn if and how well eribulin, given in combination with standard chemotherapy, can treat early-stage breast cancer compared to paclitaxel given in combination with standard…
- Trial name
- NCT01593020
- Testing
- Paclitaxel, Eribulin, 5-Fluorouracil
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction
NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)
This is a multicentre phase III open-labelled, randomised controlled trial. Eligible patients will be randomised in a 1:1 fashion between neoadjuvant and adjuvant chemotherapy (Investigator's choice modified MAGIC (ECF/ECX or…
- Conditions
- Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours, Junctional Tumours
- Trial name
- NCT01726452
- Testing
- Epirubicin, Cisplatin / Oxaliplatin, 5 Flourouracil/ Capecitabine
- Where
- 29 sites in Denmark, France and 3 more
- Volunteers
- 377 people
- Sponsor
- Cancer Trials Ireland
Breast Cancer
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
Study of the assay, Mammostrat®. to verify its utility as a predictor or outcome tool to determine whom would benefit from chemotherapy prior to surgery.
- Trial name
- NCT02067416
- Testing
- Anthracycline based chemotherapy, taxane-based chemotherapy
- Where
- United States
- Sponsor
- Jenny C. Chang, MD
Breast Cancer
Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer
The purpose of this study is to assess the efficacy of neoadjuvant weekly nab-paclitaxel followed by Adriamycin, Cyclophosphamide (AC) or Epirubicin, Cyclophosphamide (EC) or Fluorouracil,Epirubicin,Cyclophosphamide (FEC)compared…
- Trial name
- ETNA (NCT01822314)
- Testing
- Abraxane, Paclitaxel
- Where
- 67 sites in Australia, Germany and 4 more
- Volunteers
- 632 people
- Sponsor
- Fondazione Michelangelo
Breast Cancer
Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer
This study compares two chemotherapy regimens as adjuvant treatment for breast cancer. The study participants are randomly allocated to receive either 3 cycles of docetaxel followed by 3 cycles of CEF (cyclophosphamide…
- Trial name
- NCT00114816
- Testing
- capecitabine, docetaxel
- Where
- Finland
- Volunteers
- 1,500 people
- Sponsor
- Finnish Breast Cancer Group
Breast Neoplasms
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
RATIONALE: Patients with HER2-negative breast cancer not responding to initial neoadjuvant chemotherapy might have lower chances for a pathologic complete response (pCR) at definitive surgery, indicating worse prognosis.
- Trial name
- NCT05981014
- Testing
- Sentinel Lymph Node Biopsy (SLNB), Doxorubicin, Epirubicin
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Diffuse Large B Cell Lymphoma
Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma
To explore the clinical features and efficacy evaluation of large b-cell lymphoma in old age.
- Trial name
- NCT03513601
- Testing
- (R)-CHOP regimen, (R)-CVP regimen
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Mingzhi Zhang
Hepatocellular Carcinoma
Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma
The role of transarterial chemoembolization (TACE) as the standard therapy for intermediate-stage hepatocellular carcinoma (HCC) is being challenged by increasing studies which showed that liver resection (LR) is a safe and…
- Trial name
- NCT02755311
- Testing
- liver resection, transarterial chemoembolization, carboplatin
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer
Some sub-analysis has shown anthracycline-based regimens are not effective in Her-2 negative breast cancer, while capecitabine is more effective in this group of patients.
- Trial name
- NCT01354522
- Testing
- Docetaxel, Doxorubicin, Cyclophosphamide, Docetaxel, Cyclophosphamide, Capecitabine
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Peking Union Medical College Hospital
Esophageal Cancer, Gastric Cancer
Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer
The main purpose of this study is to test the safety and tolerability and effectiveness of a new treatment, EMD 72000 (matuzumab), for advanced oesophagogastric cancer in combination with the chemotherapy regimen ECX (epirubicin…
- Trial name
- NCT00113581
- Testing
- EMD 72000 (matuzumab) + ECX
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany